Cited by 416Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Long-Term Follow-up of the West of Scotland Coronary Prevention Study

Open access

Ford, Ian, Murray, Heather, Packard, Chris J., Shepherd, James, Macfarlane, Peter W., Cobbe, Stuart M.·2007·New England Journal of Medicine

DOI 10.1056/nejmoa065994

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The West of Scotland Coronary Prevention Study was a randomized clinical trial comparing pravastatin with placebo in men with hypercholesterolemia who did not have a history of myocardial infarction, with an average follow-up of approximately 5 years. The combined outcome of death from definite coronary heart disease or definite nonfatal myocardial infarction was reduced from 7.9 to 5.5% (P<0.001) in the treatment group. Extended follow-up data were obtained for approximately 10 years after completion of the trial. METHODS: For the survivors of the trial, all deaths, hospitalizations and deaths due to coronary events and stroke, and incident cancers and deaths from cancer were tracked with the use of a national computerized record-linkage system. The results were analyzed with time-to-event analyses and use of Cox proportional-hazards models. RESULTS: Five years after the trial ended, 38.7% of the original statin group and 35.2% of the original placebo group were being treated with a statin. In the period approximately 10 years after completion of the trial, the risk of death from coronary heart disease or nonfatal myocardial infarction was 10.3% in the placebo group and 8.6% in the pravastatin group (P=0.02); over the entire follow-up period, the rate was 15.5% in the placebo group and 11.8% in the pravastatin group (P<0.001). Similar percentage reductions were seen in the combined rate of death from coronary heart disease and hospitalization for coronary events for both periods. The rate of death from cardiovascular causes was reduced (P=0.01), as was the rate of death from any cause (P=0.03), over the entire follow-up period. There were no excess deaths from noncardiovascular causes or excess fatal or incident cancers. CONCLUSIONS: In this analysis, 5 years of treatment with pravastatin was associated with a significant reduction in coronary events for a subsequent 10 years in men with hypercholesterolemia who did not have a history of myocardial infarction.

Integrity signals

Registry

Crossref · 10.1056/nejmoa065994

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
Crouse, J. R., Byington, R. P., Bond, M. G., Espefand, M. A., Craven, T. E., Sprinkle, J. W., McGovern, M. E., & Furberg, C. D. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80580-3 · Cited by 607
Statins and Cancer Risk
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 600
Antibodies against MICA Antigens and Kidney-Transplant Rejection
Zou, Y., Šťastný, P., Süsal, C., Döhler, B., & Opelz, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067160 · Cited by 452

Flagged first, then by citations

Show all 23 references

Research works printed but not linked: 2

1994, Lancet, 344, 1383
Kendrick S, 1993, Health Bull (Edinb), 51, 72

Sorted by citations

Items 201–300 of 416

A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women
Hamrefors, V., Orho‐Melander, M., Krauss, R. M., Hedblad, B., Almgren, P., Berglund, G. L., & Melander, O. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p001792 · Cited by 21
A longitudinal 20 years of follow up showed a decrease in the survival of heart failure patients who maintained low LDL cholesterol levels
Charach, G., Argov, O., Nochomovitz, H., Rogowski, O., Charach, L., & Grosskopf, I. (2018) · QJM · doi:10.1093/qjmed/hcy043 · Cited by 20
Statin use and risk of basal cell carcinoma
Asgari, M. M., Tang, J. Y., Epstein, E. H., Chren, M., Warton, E. M., Quesenberry, C. P., Go, A. S., & FRIEDMAN, G. D. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.02.011 · Cited by 20
A Framework for Extension Studies Using Real-World Data to Examine Long-Term Safety and Effectiveness
Burcu, M., Manzano-Salgado, C. B., Butler, A. M., & Christian, J. B. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00322-8 · Cited by 19
External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland
Simpson, C. R., Robertson, C., Kerr, S., Shi, T., Vasileiou, E., Moore, E., McCowan, C., Agrawal, U., Stagg, H., Mulholland, R., et al. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217580 · Cited by 19
Assessment and Management of Atherosclerosis in the Athletic Patient
Parker, M. W., & Thompson, P. D. (2012) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2012.02.001 · Cited by 18
“A 10-year follow-up study documented persistent benefit among those initially assigned to statin treatment, indicating that even if statin therapy must be discontinued, there is persistent benefit to having been treated.(51) There is also probable benefit from aggressive early treatment in athletes and individuals aft…”
Background
LDL-Cholesterin und kardiovaskuläre Ereignisse: je niedriger desto besser?
Weitgasser, R., Ratzinger, M., Hemetsberger, M., & Siostrzonek, P. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0518-2 · Cited by 19
Managing hypercholesterolemia and its correlation with carotid plaque morphology in patients undergoing carotid endarterectomy
Rerkasem, K. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3729 · Cited by 19
Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications.
Karaca-Mandic, P., Swenson, T., Abraham, J., & Kane, R. (2013) · Health Services Research · doi:10.1111/1475-6773.12022 · Cited by 22
Emerging antidyslipidemic drugs
Pollex, R. L., JOY, T. R., & Hegele, R. A. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.2.363 · Cited by 19
Longitudinal follow-up study of the association between statin use and chronic periodontitis using national health screening cohort of Korean population
Kwon, M. J., Byun, S., Kim, J., Kim, J. H., Kim, S. H., Kim, N. Y., Park, H., & Choi, H. G. (2022) · Scientific Reports · doi:10.1038/s41598-022-09540-y · Cited by 18
Distribution of lifespan gain from primary prevention intervention
Finegold, J. A., Shun-Shin, M. J., Cole, G. D., Zaman, S., Maznyczka, A., Zaman, S. U., Al-Lamee, R. K., Ye, S., & Francis, D. P. (2016) · Open Heart · doi:10.1136/openhrt-2015-000343 · Cited by 19
“Few data with randomisation retained in the long term do seem to suggest a sustained hazard reduction while randomised to statin.(20) A more complex issue is the impact of smoking.”
Background
Perioperative Cardiovascular Evaluation for Orthotopic Liver Transplantation
Donovan, R. J., Choi, C., Asghar, A., Heuman, D. M., Fuchs, M. A., Bavry, A. A., & Jovin, I. S. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4371-3 · Cited by 18
Transient Dexamethasone Loading Induces Prolonged Hyperglycemia in Male Mice With Histone Acetylation in Dpp-4 Promoter
Uto, A., Miyashita, K., Endo, S., Sato, M., Ryuzaki, M., Kinouchi, K., Mitsuishi, M., Meguro, S., & Itoh, H. (2021) · Endocrinology · doi:10.1210/endocr/bqab193 · Cited by 18
The Heinz Nixdorf Recall Study and Its Potential Impact on the Adoption of Atherosclerosis Imaging in European Primary Prevention Guidelines
on behalf of the Heinz Nixdorf Investigator Group, Mahabadi, A. A., Möhlenkamp, S., Moebus, S., Dragano, N., Kälsch, H., Bauer, M., Jöckel, K., & Erbel, R. M. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0199-7 · Cited by 18
“Therefore, identifying patients at risk is a major aim in daily clinical practice [11, 12].”
Background
Novel strategies halt cardiovascular, diabetes, and cancer strips
Hu, C., Wu, Q., Hu, D., & Tkebuchava, T. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.05.002 · Cited by 18
Prevalence, awareness, treatment, and control of high LDL cholesterol in New York City, 2004.
Upadhyay, U. D., Waddell, E. N., Young, S. W., Kerker, B. D., Berger, M., Matte, T., & Angell, S. Y. (2010) · PubMed Central · Cited by 17
Undertreatment or Overtreatment With Statins: Where Are We?
García-Fernández-Bravo, I., Torres-Do-Rego, A., López-Farré, A. J., Valle, F. G., Rodríguez, P. D., & Alvarez-Sala-Walther, L. A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.808712 · Cited by 19
Muddy waters: more stormy SEAS for ezetimibe
Wierzbicki, A. S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01888.x · Cited by 17
Chromium Chloride Administration Causes a Substantial Reduction of Coronary Lipid Deposits, Aortic Lipid Deposits, and Serum Cholesterol Concentration in Rabbits
Evans, D. A. P., Tariq, M., Dafterdar, R., AlHussaini, H. F., & Sobki, S. H. (2009) · Biological Trace Element Research · doi:10.1007/s12011-009-8333-x · Cited by 17
“Following the disappointment of torcetrapib [22] and the fact that statins only prevent about 33% to 50% of coronary events [23, 24 ], there is a need for further therapeutic modalities with which to treat coronary artery disease.”
Background
Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner, M., Goetghebeur, M. M., Merikle, E. P., Pandya, A., Chu, P., & Taylor, D. C. A. (2009) · PubMed · Cited by 16
Pathological Characteristics, Biochemical Recurrence and Functional Outcome in Radical Prostatectomy Patients on Statin Therapy
Kontraros, M., VARKARAKIS, I. M., Ntoumas, K., & Deliveliotis, C. (2013) · Urologia Internationalis · doi:10.1159/000346751 · Cited by 16
Statins and safety: can we finally be reassured?
Kohli, P., & Cannon, C. P. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61544-4 · Cited by 16
Long-Term Incidence of Stroke and Dementia in ASCOT
Whiteley, W. N., Gupta, A. K., Godec, T. R., Rostamian, S., Whitehouse, A., Mackay, J. A., & Sever, P. (2021) · Stroke · doi:10.1161/strokeaha.120.033489 · Cited by 18
Association of Statin Use with the Risk of Incident Prostate Cancer: A Meta-Analysis and Systematic Review
Xu, M., An, Y., Liu, C., Xu, J., Zhong, X., Zeng, N., Sun, J., Xia, Q., & Wang, S. (2022) · Journal of Oncology · doi:10.1155/2022/7827821 · Cited by 16
Drug-Drug Interactions Between Raltegravir and Pravastatin in Healthy Volunteers
van Luin, M., Colbers, A. P. H., Kolmer, E. W. J. V. E.-B., Wissen, C. P. W. G. M. V.-V., Schouwenberg, B., Hoitsma, A., da Silva, H. G., & Burger, D. M. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181d9a354 · Cited by 16
Changes in carotid plaque tissue composition in subjects who continued and discontinued statin therapy
Du, R., Zhao, X.-Q., Cai, J., Cui, B., Wu, H.-M., & Ye, P. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.01.004 · Cited by 16
PCSK9 inhibitors may improve cardiovascular outcomes—Can we afford them?
Arbel, R., Hammerman, A., Triki, N., & Greenberg, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.126 · Cited by 16
Long-Term Follow-up of the West of Scotland Coronary Prevention Study
DeFilippis, A. P., Bansal, S., & Blumenthal, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc076463 · Cited by 16
E-health data to support and enhance randomised controlled trials in the United Kingdom
Harron, K. L., Gamble, C. L., & Gilbert, R. E. (2014) · Clinical Trials · doi:10.1177/1740774514562030 · Cited by 14
“deaths, cancer outcomes or educational outcomes).(7) Additionally, e-health data could contribute to assembling core outcome sets (e.”
Background
Drugs and lifestyle for the treatment and prevention of coronary artery disease: comparative analysis of the scientific basis
da Luz, P. L., Nishiyama, M., & Chagas, A. C. P. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500111 · Cited by 14
Long-Term Outcomes of Short-Term Statin Use in Healthy Adults: A Retrospective Cohort Study
Mansi, I. A., English, J. L., Zhang, S., Mortensen, E. M., & Halm, E. A. (2016) · Drug Safety · doi:10.1007/s40264-016-0412-2 · Cited by 16
Cumulative in-trial and post-trial effects of blood pressure and lipid lowering
Hirakawa, Y., Arima, H., Rodgers, A., Woodward, M., & Chalmers, J. P. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001233 · Cited by 16
Initiating statins in the elderly: the evolving challenge
Walker, D. B., & Jacobson, T. A. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f7cd6d · Cited by 15
Coronary Artery Disease Prevention
Sherazi, S., & Block, R. (2009) · Springer eBooks · doi:10.1007/978-1-84882-185-9_2 · Cited by 15
Implementation of an early rule-out pathway for myocardial infarction using a high-sensitivity cardiac troponin T assay
Sandeman, D., Syed, M. B. J., Kimenai, D. M., Lee, K. K., Anand, A., Joshi, S. S., Dinnel, L., Wenham, P. R., Campbell, K. L., Jarvie, M., et al. (2021) · Open Heart · doi:10.1136/openhrt-2021-001769 · Cited by 14
Cardiovascular morbidity and mortality in diabetes mellitus: prediction and prognosis.
Astrup, A. S. (2011) · PubMed · Cited by 14
Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study
Pavlović, J., Greenland, P., Deckers, J. W., Kavousi, M., Albert Hofman, D., Ikram, M. A., Franco, O. H., & Leening, M. J. G. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317743352 · Cited by 14
Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome
Parthan, A., Leahy, K. J., O’Sullivan, A. K., Iakoubova, O. A., Bare, L. A., Devlin, J. J., & Weinstein, M. C. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0054-5 · Cited by 14
High Receipt of Statins Reduces the Risk of Lung Cancer in Current Smokers With Hypercholesterolemia: The National Health Insurance Service–Health Screening Cohort
Kwon, Y., You, N.-Y., Lee, J., Kim, J., & Kang, H. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.009 · Cited by 14
Investigating the long-term legacy of statin therapy
Takata, K., Psaltis, P. J., & Nicholls, S. J. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.10 · Cited by 14
Degree of Risk Factor Control and Incident Cardiovascular Diseases in Patients With Hypertension
Kou, M., Wang, X., Ma, H., Li, X., Heianza, Y., & Qi, L. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.05.008 · Cited by 12
A Point‐by‐Point Response to Recent Arguments Against the Use of Statins in Primary Prevention
Joshi, P. H., Chaudhari, S., Blaha, M. J., Jones, S. R., Martin, S. S., Post, W. S., Cannon, C. P., Fonarow, G. C., Wong, N. D., Amsterdam, E. A., et al. (2012) · Clinical Cardiology · doi:10.1002/clc.22016 · Cited by 13
The Heart Failure and Optimal Outcomes from Pharmacy Study (HOOPS): Rationale, Design, and Baseline Characteristics
Lowrie, R., Mair, F. S., Greenlaw, N., Forsyth, P., McConnachie, A., Richardson, J., Khan, N., Morrison, D., Messow, C., Rae, B., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr083 · Cited by 13
The Year in Atherothrombosis
Sanz, J., Moreno, P., & Fuster, V. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.018 · Cited by 13
The Effect of Statins on the Incidence and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis
Symvoulidis, P., Tsioutis, C., Zamboglou, C., & Agouridis, A. P. (2023) · Current Oncology · doi:10.3390/curroncol30070488 · Cited by 12
Discontinuation of Unnecessary Medications in Older Adults
Brandt, N., & Stefanacci, R. G. (2011) · The Consultant Pharmacist · doi:10.4140/tcp.n.2011.845 · Cited by 12
The Anglo-Scandinavian Cardiac Outcomes Trial
Sever, P. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.187070 · Cited by 12
Synergies From Integrating Randomized Controlled Trials and Real‐World Data Analyses
Najafzadeh, M., Gagne, J. J., & Schneeweiß, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.873 · Cited by 12
Statins and risk of cancer: A meta-analysis of randomized, double-blind, placebo-controlled trials
Kim, M. K., Myung, S., Tran, B. T., & Park, B. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_214_17 · Cited by 12
Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study—Observational Study
Zhao, X.-Q., Phan, B. A. P., Davis, J., Isquith, D. A., Dowdy, A. A., Boltz, S., Neradilek, M. B., Monick, E. A., Brockenbrough, A., Frechette, E. E. H. S., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.013 · Cited by 11
Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin
Engel, S. S., Anderson, K. M., Hanson, Musliner, & Steinberg, H. O. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s44330 · Cited by 11
Statins: in the beginning
Lyons, K., & Harbinson, M. (2009) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2009.425 · Cited by 11
Association between plasma lipid levels during acute coronary syndrome and long-term malignancy risk. The ABC-4* study on heart disease
Berton, G. S., Cordiano, R., Cavuto, F., Bagato, F., Mahmoud, H., & Pasquinucci, M. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1092-5 · Cited by 10
Organ memory: a key principle for understanding the pathophysiology of hypertension and other non-communicable diseases
Itoh, H., Kurihara, I., & Miyashita, K. (2018) · Hypertension Research · doi:10.1038/s41440-018-0081-x · Cited by 10
Prevention of Atherosclerotic Cardiovascular Disease
Daniels, S. R. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.082 · Cited by 11
“Presumably, both groups are treated with the intervention (statins) thereafter, but the intervention group continues to have a lower rate of events (9).”
Background
Diabetes and Cardiovascular Disease
Bitzur, R. (2011) · Diabetes Care · doi:10.2337/dc11-s256 · Cited by 10
“It seems that the full benefit cannot be achieved by starting treatment 5 years later (24,25).”
Background
Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure?
Alba, A. C., & Delgado, D. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.7.2.147 · Cited by 9
Primary prevention of cardiovascular disease with statins: cautionary notes
Goldstein, M. R., Mascitelli, L., & Pezzetta, F. (2009) · QJM · doi:10.1093/qjmed/hcp099 · Cited by 9
Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial
Ohsfeldt, R. L., OLSSON, A. G., Jensen, M. M., Gandhi, S. K., & Paulsson, T. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.627073 · Cited by 8
Statin Use is Not Associated with Future Long-Term Care Admission: Extended Follow-Up of Two Randomised Controlled Trials
Burton, J. K., Papworth, R., Haig, C. E., McCowan, C., Ford, I., Stott, D. J., & Quinn, T. J. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0560-4 · Cited by 8
“Our previous work on the long-term follow-up of the WOSCOPS and PROSPER trials has demonstrated the additional scientific value of extended follow-up of these clinical trial populations and of record linkage to national datasets.(1)”
BackgroundInfluential
Does the Benefit from Statin Therapy Extend Beyond 5 Years?
Bulbulia, R. A., & Armitage, J. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0297-1 · Cited by 8
Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial
Nakao, K., Noguchi, T., Asaumi, Y., Morita, Y., Kanaya, T., Fujino, M., Hosoda, H., Yoneda, S., Kawakami, S., Nagai, T., et al. (2018) · Trials · doi:10.1186/s13063-017-2353-1 · Cited by 7
Can statins reduce risk of lung cancer, especially among elderly people? A meta-analysis.
Deng, Z., Zhang, S., Yi, L., & Chen, S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2013.11.02 · Cited by 8
“With our selection criteria, we identified 23 studies to our meta-analysis, including 15 observational studies (8,9,30-42) (8 case-control studies, 7 cohort studies) and 8 randomized-controlled studies (43-50) (Figure 1).”
MethodInfluential
Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis
Sun, H., Yuan, Y., Wang, P., Cai, R., Xia, W., Huang, R., & Wang, S. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0147-6 · Cited by 8
Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis
Keller, H., Hirsch, O., Kaufmann-Kolle, P., Krones, T., Becker, A., Sönnichsen, A. C., Baum, E., & Donner‐Banzhoff, N. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-623 · Cited by 8
Impact of Total Risk Management on Coronary Plaque Regression in Diabetic Patients with Acute Coronary Syndrome
Naito, R., Miyauchi, K., Daida, H., Morimoto, T., Hiro, T., Kimura, T., Nakagawa, Y., Yamagishi, M., Ozaki, Y., Matsuzaki, M., et al. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.31948 · Cited by 7
Lipid-Lowering Medication and Outcomes After Anatomical and Functional Imaging in Suspected Coronary Artery Disease
Maaniitty, T., Mäenpää, M., Harjulahti, E., Kujala, I., Stenström, I., Nammas, W., Knuuti, J. M., & Saraste, A. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.07.009 · Cited by 7
Lifetime Risk of Cardiovascular Disease: The Next Generation in Risk Prediction
Bleakley, C., Millar, A., Harbinson, M., & McVeigh, G. E. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.025 · Cited by 7
Impact de la prise de statines sur les groupes à risques de progression de D’Amico et la survie sans récidive biologique après prostatectomie totale
Misraï, V., Do, C., Jm, L., Elman, B., Latorzeff, I., Portalez, D., & Grosclaude, P. (2011) · The French Journal of Urology · doi:10.1016/j.purol.2011.11.001 · Cited by 7
“Statines au moment de la chirurgie 2,6 [1,4—4,7] Diabète 2,6 [1,1—6,1] IMC ≥ 30 kg/m2 0,9 [0,5—1,67] Marge chirurgicale positive 3,2 [1,7—5,8] Krane et al.”
BackgroundInfluential
Late effect of treatment for reducing cardiovascular risk – A hypothesis on cardiometabolic therapeutic memory
Jermendy, G. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.01.034 · Cited by 6
“The results of the long-term follow-up of the WOSCOPS were published recently [18].”
Background
Statines en prévention primaire des événements cardiovasculaires
Adham, S., Miranda, S., Doucet, J., Levesque, H., & Benhamou, Y. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.08.002 · Cited by 7
Intensive statin therapy for Indians: Part-I. Benefits.
Enas, E. A., Pazhoor, H. C., Kuruvila, A. T., & Vijayaraghavan, K. (2011) · PubMed · Cited by 7
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Collins, P. D., & Sattar, N. A. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0795-9 · Cited by 7
Statins, Primary Prevention, and Overall Mortality
Prasad, V. K. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2974 · Cited by 6
“9 median years of follow-up) (6), but Taylor used long-term outcomes that extended 10 years beyond the trial’s completion, after unmasking and open-label use (7).”
Latest Updates on Lipid Management
Egom, E. E. A., Pharithi, R. B., Hesse, S., Starr, N., Armstrong, R. L., Sulaiman, H. M., Gazdíková, K., Mozos, I. M., Čaprnda, M., Kubatka, P., et al. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00306-8 · Cited by 5
Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women
Sun, M., Lemaçon, A., Legault, M., Asselin, G., Provost, S., Aschard, H., Barhdadi, A., Zada, Y. F., Valois, D., Mongrain, I., et al. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-021-00221-z · Cited by 6
Landmark position paper on paediatric familial hypercholesterolaemia from the EAS Consensus Panel
Stock, J. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.021 · Cited by 6
“Given the legacy effect observed from statin trials (although not specifically in FH patients) [8,9], there is likely to be greater benefit in those starting treatment earlier rather than later.”
Background
Lipid-lowering drugs and risk for cancer
Pedersen, T. R. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0053-3 · Cited by 6
The Role of Statin Therapy for Primary Prevention: What is the Evidence?
Ascunce, R. R., Berger, J. S., WEINTRAUB, H. S., & Schwartzbard, A. Z. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0229-0 · Cited by 6
TRENDS OF LIPID ABNORMALITIES IN PAKISTANI TYPE-2 DIABETES MELLITUS PATIENTS: A TERTIARY CARE CENTRE DATA
Bhatti, S. M., Dhakam, S. H., & Khan, M. A. (2009) · Pakistan Journal of Medical Sciences · Cited by 6
Biphasic Regulation of Intracellular Calcium by Gemfibrozil Contributes to Inhibiting L6 Myoblast Differentiation: Implications for Clinical Myotoxicity
Liu, A., Yang, J., Gonzalez, F. J., Cheng, G. Q., & Dai, R. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100312h · Cited by 6
Strategies to meet the need for long-term data
Chalmers, J. P., Woodward, M., Borghi, C., Manolis, A. J., & Mancia, G. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000987 · Cited by 6
Public perceptions, knowledge and awareness of cholesterol management in Singapore: a prospective pilot study
Th, A., Go, Y. Y., Lp, L., & Chua, T. (2013) · Singapore Medical Journal · doi:10.11622/smedj.2013008 · Cited by 6
How Statins May Increase Prostate Cancer
Goldstein, M. R., Mascitelli, L., & Pezzetta, F. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2776 · Cited by 6
Measurement of cardiac troponin for exclusion of myocardial infarction – Authors' reply
Shah, A. S. V., Anand, A., Chapman, A. R., Newby, D. E., & Mills, N. L. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30517-7 · Cited by 6
Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review
Kim, H., & Kim, J. K. (2022) · The World Journal of Men s Health · doi:10.5534/wjmh.210139 · Cited by 6
A Reappraisal of the Safety and Cost-Effectiveness of Statin Therapy in Primary Prevention
Bleakley, C., Pumb, R., Harbinson, M., & McVeigh, G. E. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.03.033 · Cited by 5
Challenge of Surrogate Endpoints
Furgerson, J. L., Hannah, W. N., & Thompson, J. C. (2012) · Southern Medical Journal · doi:10.1097/smj.0b013e318249891e · Cited by 5
Temporal Gene Expression Analysis of Human Coronary Artery Endothelial Cells Treated With Simvastatin
Zhang, L. Q., Ma, S.-F., Grigoryev, D. N., Lavoie, T. L., Xiao, H. Q., Setterquist, R. A., Li, H., Jacobson, J. R., Garcia, J. G. N., & YE, A. S. Q. (2008) · Gene Expression · doi:10.3727/105221608786883834 · Cited by 5
Cholecystectomy or Cholelithiasis – a Missed Marker for Hyperlipidaemia? A Combined Retrospective and Prospective Study
Sabanathan, S. (2008) · Gastroenterology Research · doi:10.4021/gr2008.11.1246 · Cited by 5
Statins for Prevention of Cardiovascular Disease in Adults: Systematic Review for the U.S. Preventive Services Task Force
Rockville, F. L. (2015) · Cited by 5
Lipid-modifying and antiatherosclerotic drugs
Gotto, A. M., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00019-3 · Cited by 5
Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary
Bueno, H., de Graeff, P., Richard‐Lordereau, I., Emmerich, J., Fox, K. A. A., Friedman, C. P., Gaudin, C., Elgazayerly, A., Goldman, S., Hemmrich, M., et al. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616649859 · Cited by 5
O Futuro da Saúde / Aptidão Física / Desempenho Esportivo
Foster, C., Cortis, C., Fusco, A., Bok, D., Boullosa, D. A., Capranica, L., de Koning, J. J., Haugen, T. A., Silva, I. O., Periara, J., et al. (2017) · Fronteiras Journal of Social Technological and Environmental Science · doi:10.21664/2238-8869.2017v6i3.p187-211 · Cited by 5
Cholesterol-lowering and cancer in the prevention of cardiovascular disease
Oliver, M. F. (2010) · QJM · doi:10.1093/qjmed/hcp186 · Cited by 5
Association between serum lipids, polyunsaturated fatty acids, and prognosis in maintenance hemodialysis patients
Tanaka, Y., Ohya, M., Yano, T., Minakata, T., Higashiura, M., Yamamoto, S., Mima, T., Negi, S., Nakata, H., Otani, H., et al. (2020) · Hemodialysis International · doi:10.1111/hdi.12892 · Cited by 4
Long-term results from statin trials: answers but more unresolved questions
Backer, G. D. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr303 · Cited by 4
Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope?
Barkas, F., Rizzo, M., DiNicolantonio, J. J., & Liberopoulos, E. N. (2013) · Clinical Lipidology · doi:10.2217/clp.13.29 · Cited by 4
Effects of Simvastatin and Vitamin E on Diet-induced Hypercholesterolemia in Rats
Mahmoud, H. M., Zaki, H. F., Sherbiny, G. A. E., & El‐Latif, H. A. A. (2014) · British Journal of Pharmacology and Toxicology · doi:10.19026/bjpt.5.5412 · Cited by 4

Authors: Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M.
Affiliations: University of Glasgow (GB)
ORCID: Ford, Ian
Packard, Chris J.
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-10-11
Volume: 357
Issue: 15
Pages: 1477-1486
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa065994
OpenAlex: W1973491874
Cited by: 416
References: 23
Citations by year: 2026: 4 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 9 · 2020: 7 · 2019: 14 · 2018: 23 · 2017: 26 · 2016: 29 · 2015: 19 · 2014: 34 · 2013: 46 · 2012: 28
FWCI: 36.61
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, statins, hypercholesterolemia, coronary artery disease, myocardial infarction, long-term follow-up, secondary prevention, cardiovascular mortality, cancer incidence, men
MeSH terms: Anticholesteremic Agents, Coronary Disease, Follow-Up Studies, Humans, Hypercholesterolemia, Male, Middle Aged, Myocardial Infarction, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Term Follow-up of the West of Scotland Coronary Prevention Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks